OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
Long R3 insulin-like growth factor-1. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Low reported | 20 mcg | 1× daily | 0.12 mL | 12 u | 50 doses | |
| Standard | 40 mcg | 1× daily | 0.24 mL | 24 u | 25 doses | |
| Upper reported | 60 mcg | 1× daily | 0.36 mL | 36 u | 16 doses |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 20 mcg | daily | 0.12 mL | 12 u | 14 | 0.28 mg |
| Weeks 3–4 | 40 mcg | daily | 0.24 mL | 24 u | 14 | 0.56 mg |
| Week 5 onward per 4 weeks from here on |
60 mcg | daily | 0.36 mL | 36 u | 28 | 1.68 mg |
An IGF-1 analogue engineered to resist binding-protein sequestration, giving far longer activity than native IGF-1. Carries genuine hypoglycaemia risk. Widely used as a cell-culture supplement; human research use is not supported by trial data.
Buy IGF-1 LR3this peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
Recombinant somatropin. An approved prescription drug with well-defined indications and a substantial adverse-effect profile inclu…
A truncated IGF-1 variant with roughly tenfold higher potency at the receptor but a very short half-life, hence its reputation as …
Every compound compared in one table: dose range, how often, half-life and evidence tier.